文献速递免疫规划传染病防控与疫情报告

Sabin株灭活脊髓灰质炎疫苗在IV期临床试验中的免疫原性与安全性

Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.
PubMed 文献 · Vaccine · 2021-01-22

该IV期临床试验在1200名婴儿中评估了三批sIPV的批间一致性免疫原性,并对20019名婴儿进行主动监测、29683名婴儿通过AEFI系统被动监测安全性。结果显示I、II、III型平均血清阳转率分别为99.83%、98.93%和99.44%,批间比较无差异,大规模人群中安全性良好。

要点

  • 三批sIPV的I、II、III型血清阳转率均高于98.9%,批间无差异。
  • 大规模安全性监测中多数不良反应发生在首剂后0-30天,发生率低。
  • sIPV批间一致性和大规模安全性良好,可作为全球消灭脊灰的候选疫苗。

核心结论

  • sIPV具有良好的批间一致性和大规模人群安全性,有资格作为全球消灭野生和疫苗衍生脊髓灰质炎病毒的疫苗之一。

研究设计与样本

  • IV期临床试验,免疫原性评估纳入1200名婴儿比较三批商业sIPV的批间一致性;安全性评估对20019名婴儿主动监测,并通过中国AEFI报告系统对29683名婴儿被动监测。

主要发现

  • 免疫原性评估中三组I、II、III型平均血清阳转率分别为99.83%、98.93%和99.44%。
  • 批间两两比较中血清阳转率和GMT比值均无差异。
  • 大规模安全性评估中多数不良反应发生在首剂后0-30天,常见局部和全身反应与III期临床试验相似,主动和被动监测中发生率均低。

关键数值与推荐

  • I型血清阳转率99.83%,II型98.93%,III型99.44%(1200名婴儿,三批sIPV)。
  • 批间两两比较血清阳转率和GMT比值无差异(未报告具体P值)。
  • 主动监测20019名婴儿,被动监测29683名婴儿,不良反应发生率低。

临床怎么用

  • sIPV可用于婴儿常规免疫,批间一致性支持其大规模接种。
  • 接种后0-30天应关注局部和全身反应,但发生率低。
  • 该疫苗可作为消灭脊髓灰质炎野毒株和疫苗衍生株的候选疫苗之一。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a recently launched novel vaccine used as one of the vaccines for the final eradication of polios worldwide, complete data on the consistency and immunogenicity characteristics of the inactivated poliomyelitis vaccine made from the Sabin strain (sIPV) and its safety in large-scale populations are required to support the future use of this vaccine worldwide. A phase IV clinical trial was conducted to perform an immunogenicity evaluation of lot-to-lot consistency of three commercial batches of sIPV in 1200 infants and to investigate the vaccine's safety on a large-scale in 20,019 infants for active monitoring and 29,683 infants for passive monitoring through the Adverse Event Following Immunization (AEFI) reporting system in China. In the immunogenicity evaluation, the average seroconversion rates for type I, type II and type III of the three groups were 99.83%, 98.93% and 99.44%, respectively. No differences in the seroconversion rate and the GMT ratios were noted in the pair-to-pair comparisons. In the large-scale safety evaluation, most adverse reactions occurred 0-30 days after the first doses, and the common local and systemic reactions were similar to those in the phase III clinical trial, with low incidence in both activated and passive monitoring. In conclusion, sIPV exhibits good lot-to-lot consistency and safety in large-scale populations; thus, it is qualified to serve as one of the vaccines for use in eradicating all wild and vaccine-derived polioviruses worldwide in the near future. Clinic Trial Registration. NCT04224519 and NCT04220515.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jiang R, Liu X, Sun X, et al. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine. 2021. PMID: 33487470. doi:10.1016/j.vaccine.2021.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。